Abstract
Proliferation signal inhibitors (PSI) could help to lower the calcineurine inhibitors level to minimize their toxicity and improve long-term graft survival. Side effects of this drugs are specific and must been known. Hyperlipidemia and cutaneous side-effects are the most frequent, angioedema and interstital pneumonitis the most serious. In majority of cases, early and adapted management could limit the impact of these side effects.
MeSH terms
-
Angioedema / chemically induced
-
Angioedema / prevention & control
-
Calcineurin Inhibitors
-
Cicatrix / prevention & control
-
Cyclosporine / adverse effects
-
Graft Rejection / prevention & control*
-
Graft Survival
-
Hematologic Diseases / chemically induced
-
Hematologic Diseases / prevention & control
-
Humans
-
Hyperlipidemias / chemically induced
-
Hyperlipidemias / prevention & control
-
Immunosuppressive Agents / adverse effects*
-
Intracellular Signaling Peptides and Proteins / antagonists & inhibitors*
-
Kidney Diseases / chemically induced
-
Kidney Diseases / prevention & control
-
Lymphocele / chemically induced
-
Lymphocele / prevention & control
-
Pneumonia / chemically induced
-
Pneumonia / prevention & control
-
Protein Serine-Threonine Kinases / antagonists & inhibitors*
-
Sirolimus / adverse effects
-
Sirolimus / therapeutic use
-
Skin Diseases / chemically induced
-
Skin Diseases / prevention & control
-
TOR Serine-Threonine Kinases
Substances
-
Calcineurin Inhibitors
-
Immunosuppressive Agents
-
Intracellular Signaling Peptides and Proteins
-
Cyclosporine
-
MTOR protein, human
-
Protein Serine-Threonine Kinases
-
TOR Serine-Threonine Kinases
-
Sirolimus